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Background 
• Desmoid tumor represents an intermediate grade neoplasm with a 
striking predilection for locally invasive growth and recurrence 
following resection 
• More effective, well-tolerated non-surgical treatment options are 
needed 
• Current approaches 
• If feasible, watchful waiting is the preferred approach 
• 20-30% spontaneous regression 
• In situations where treatment is indicated, the following 
approaches are utilized 
• Surgery is the primary approach if minimal morbidity is   
     anticipated 
• Medical therapies 
• Cytotoxic drugs 
• Tyrosine kinase inhibitors 
• Hydroxyurea 
• Gamma secretase inhibitors 
• mTOR Inhibitor Rationale 
• Desmoid tumor is well-known to be associated with 
deregulation of the APC/β-catenin pathway 
• Deregulation of the mTOR cell proliferation/survival pathway 
may play an important role in tumor biology when the APC/β-
catenin pathway is disrupted 
• The mTOR inhibitor sirolimus is attractive as a potential targeted 
therapy for desmoid tumor 
• Well-tolerated in children and young adults 
• Can be given orally in tablet or liquid formulation 
Objectives 
• Primary 
1. To determine whether mTOR pathway activation decreases in 
patients with surgically resectable desmoid tumor that is 
removed following pre-operative treatment with sirolimus 
• Secondary 
1. To assess whether sirolimus improves desmoid tumor-associated 
pain 
2. To begin to explore whether pre-operative sirolimus decreases 
tumor recurrence following surgical removal of desmoid tumor 
felt to be at high-risk for recurrence because of size and/or 
anatomic site 
3. To assess the safety and tolerability of pre-operative sirolimus in 
patients with desmoid tumor 
Methods 
• Multi-institutional study open and actively accruing patients 
• Eligibility criteria 
• <30 years of age 
• Surgery is planned to remove their desmoid tumor and either 
• (a) the desmoid tumor has already recurred  after a prior 
surgery or 
• (b) the newly diagnosed or previously unresected disease is 
judged to be at high risk for recurrence due to its size (>5 cm) 
or location at an anatomic site making it unlikely to be 
resected with negative margins (e.g., adjacent to 
neurovascular structures) 
• Patients with germline APC causing FAP/Gardner’s syndrome 
• This is an IRB-approved study and patient consent is required 
Figure 1. Experimental Design Schema 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
• Nine of an anticipated 15 total patients have enrolled to date 
• Ages have ranged from 5 to 28 years 
• All patients have been able to take the pre-operative sirolimus as 
prescribed and undergone surgery within the protocol-directed time 
frame 
• All toxicities have been as expected and Common Terminology 
Criteria for Adverse Events grade 1 and 2 only except for one grade 3 
neutropenia 
• No post-operative complications have been reported 
• IHC staining is ongoing for p4E-BP1, p70S6K, and pAKT (Figure 2) 
• Pain assessment measurements and anatomical imaging are being 
performed at designated surveillance intervals 
Histologic Assessment 
• Tissue 
• Pre-therapy biopsy 
• Post-therapy biopsy 
• Archived specimens (future analysis) 
• Paired, pre-treatment 
• Non-chemotherapy treatment 
Figure 2. Representative pre- and post-operative IHC staining for mTOR 
pathway proteins p4E-BP1, p70S6K, and pAKT in desmoid tumor 
Conclusion 
• Sirolimus appears to be well-tolerated when administered in the pre-
operative setting to children and young adults with desmoid tumor 
• Surgery is feasible and safe immediately after completing therapy 
• Formal assessment of the mTOR pathway by IHC analysis will take 
place at study completion 
• The study continues to actively accrue 
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